Central nervous system (CNS) penetration of homoharringtonine (HHT)
- 1 January 1987
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 5 (1) , 77-81
- https://doi.org/10.1007/bf00162769
Abstract
Generally tritiated homoharringtonine ([3H]HHT, 150 μCi, 430 μg) was administered intravenously to seven patients at varying times before surgical resection of malignant brain tumor. Plasma, urine, cerebrospinal fluid (CSF), and tumor specimens were obtained during surgery, and the concentrations of HHT, its major metabolite, and [3H]HHT equivalent were determined chromatographically and radiochemically. For [3H]HHT equivalent, the concentration in tumor ranged from 0.6 to 4.3 ng/g and the ratio of tumor to plasma concentration from 0.5 to 1.8. In one patient who had CSF available for drug determination, the CSF to plasma ratio of total [3H]HHT was 0.3 at 45 minutes after drug administration and less than 0.2 ng/ml was unchanged HHT. For unchanged HHT, drug concentration in tumor ranged from undetectable (4 patients) to 1.8 ng/g. A major metabolite of HHT was detectable in the tumor specimens of all the patients. These results indicate that homoharringtonine can penetrate into brain tumors; in 3 patients with brain tumors, the ratios of HHT concentration in the tumor to that in the concurrent plasma were greater than one.This publication has 2 references indexed in Scilit:
- PHASE-I CLINICAL INVESTIGATION OF HOMOHARRINGTONINE1984
- Inhibition of Protein Synthesis in Intact HeLa CellsAntimicrobial Agents and Chemotherapy, 1975